Lobbying client

TRYGG PHARMA, INC.

Pharmaceutical research and development.

The register keeps a separate record of this client for every firm that files for it and every spelling of its name. All 2 of its records are shown together here.

Filings
14
Filed by
2
Reported in-house
—
Reported by firms
$340,000

Reported lobbying by year

The larger of in-house and firm-reported each year, $ thousands 2012 to 2014

Filings

8 filings for 2013, newest first.
Filing Filed by Amount
4th Quarter - Report
4th Quarter 2013
FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC) $60,000 reported
4th Quarter - Termination
4th Quarter 2013
ENGEL & NOVITT, LLP — reported
3rd Quarter - Report
3rd Quarter 2013
FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC) $40,000 reported
3rd Quarter - Report (No Activity)
3rd Quarter 2013
ENGEL & NOVITT, LLP — reported
2nd Quarter - Report
2nd Quarter 2013
ENGEL & NOVITT, LLP $10,000 reported
2nd Quarter - Report
2nd Quarter 2013
FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC) $40,000 reported
1st Quarter - Report
1st Quarter 2013
ENGEL & NOVITT, LLP — reported
1st Quarter - Report
1st Quarter 2013
FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC) $60,000 reported

Filed by

Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.

FirmReportsAmount
FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC) 7 $300,000
ENGEL & NOVITT, LLP 5 $40,000

Issues lobbied

How many report sections named each issue, counting the current version of each report.

IssueCodeMentions
Health Issues HCR 12

From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.